drugset / Trial / NCT04641962
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to evaluate the dose response of Bocidelpar on functional improvement relative to placebo, safety, and tolerability in participants with Primary Mitochondrial Myopathy.
Timeline
- Start
- 2021-05-24
- Primary completion
- 2024-05-08
- Completion
- 2024-05-08
Outcome
Outcome not reported
Stopped: “Due to failure to meet the pre-specified criteria for efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bocidelpar | Small molecule | 30 mg | Oral |
| Subject | Bocidelpar | Small molecule | 75 mg | Oral |